C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer

European Journal of Cancer

Volumn 38, Issue 4, 2002, Pages 535-542

  Sjostrom J ^a   Collan, J ^a   Von Boguslawski, K ^a   Franssila, K ^a   Bengtsson, N O ^b   Mjaaland, I ^c   Malmstrom P ^d   Ostenstad B ^e   Wist, E ^f   Valvere, V ^g   Bergh, J ^h   Skiold Petterson D ⁱ   Saksela, E ^a   Blomqvist, C ^j  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^g Estonian Cancer Center   (Estonia)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ DANDERYD HOSPITAL   (Sweden)

^j UPPSALA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Breast cancer; c erbB 2; Chemotherapy; Docetaxel; Predictive factor

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOCETAXEL; FLUOROURACIL; METHOTREXATE; PARAFFIN; POLYCLONAL ANTIBODY; PROTEIN; PROTEIN C ERB 2; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOGENE C ERB; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 0036191721     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00403-8     Document Type: Article

References (21)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. HER-2/neu (c-erb-B2) gene and protein in breast cancer
3. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
4. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the scandinavian breast group
5. Reporting results of cancer treatment
6. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
7. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) breast cancer study
8. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
9. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
10. cerbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
11. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
12. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
13. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer
14. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
15. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
16. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi
17. C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer
18. Prediction of response to primary chemotherapy for operable breast cancer
19. Response to mitoxantrone in advanced breast cancer: Correlation with expression of c-erbB-2 protein and glutathione S-transferases
20. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease
21. Improving the quality of reporting of randomised controlled trials: The CONSORT statement